Zenas BioPharma is an immunotherapy drug developer dedicated to the development of immunotherapy drugs. Recently, it received a Series B financing of 118 million US dollars. The round was led by Enavate Sciences, with participation from Longitude Capital, Vivo Capital, Rock Springs Capital, Perceptive Advisors, Agent Capital, Pivotal bioVenture Partners and Superstring Capital. In addition, the company’s existing investors Fairmount, Wellington Management, Tellus BioVentures, Quan Venture Fund and Xencor also participated in the investment.
This article is reproduced from: https://www.itjuzi.com/investevent/13655680
This site is for inclusion only, and the copyright belongs to the original author.